Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Claims - The lawsuit claims that Nutex Health Inc. made false statements and concealed information regarding its third-party vendor HaloMD, which allegedly engaged in fraudulent activities to defraud insurance companies [2]. - It is alleged that revenues from Nutex's engagement with HaloMD were unsustainable due to the fraudulent conduct [2]. - The company purportedly overstated its remediation efforts regarding material weaknesses in its internal controls over financial reporting [2]. - Nutex is accused of improperly accounting for stock-based compensation obligations, treating them as equity instead of liabilities [2]. - The allegations suggest that these issues increased the risk of Nutex failing to file certain financial reports with the SEC in a timely manner [2]. - Consequently, the lawsuit asserts that Nutex's business and financial prospects were overstated, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its expertise in complex securities litigation [4].

Core Viewpoint - Nutex Health Inc. is facing allegations of issuing materially false and misleading statements during the class period from August 8, 2024, to August 14, 2025, related to its financial reporting and business practices [1]. Group 1: Allegations Against Nutex Health Inc. - The complaint alleges that Nutex's third-party vendor, HaloMD, engaged in fraudulent activities to defraud insurance companies, leading to unsustainable revenue [1]. - Nutex is accused of overstating its remediation efforts regarding material weaknesses in its internal controls over financial reporting [1]. - The company improperly classified stock-based compensation obligations as equity instead of liabilities, increasing the risk of delayed financial report filings with the SEC [1]. Group 2: Class Action Details - Shareholders who purchased shares of Nutex during the specified class period are encouraged to register for the class action, with a deadline of October 21, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

Core Viewpoint - Nutex Health Inc. is facing significant legal challenges while preparing to release its quarterly earnings, with mixed financial metrics indicating both potential and risk for investors [1][2][6]. Financial Performance - The company is expected to report an earnings per share (EPS) of -$5.43 and projected revenue of approximately $210.89 million for the upcoming quarter [1][6]. - Nutex has a price-to-earnings (P/E) ratio of approximately 6.84, suggesting a low market valuation of its earnings [4][6]. - The price-to-sales ratio stands at about 0.74, indicating a relatively low valuation compared to its sales [4][6]. - The enterprise value to sales ratio is 1.15, which is slightly higher than its total sales [4]. Legal Challenges - The company is currently involved in a class-action lawsuit for alleged securities law violations, with a deadline of October 21, 2025, for investors to file as lead plaintiffs [2][6]. - Allegations include fraudulent activities and misleading investors about the company's financial health, particularly through deceptive billing strategies linked to its vendor HaloMD [2][3]. Financial Health Indicators - Nutex's earnings yield is reported at 14.63%, indicating a potential return on investment for shareholders [5][6]. - The debt-to-equity ratio is 1.73, reflecting significant debt usage compared to equity [5]. - A current ratio of 2.27 suggests a strong ability to cover short-term liabilities with short-term assets, providing some reassurance to investors despite ongoing legal issues [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Nutex Health Inc. regarding a class action lawsuit due to allegations of misleading statements and fraudulent activities during a specified class period [1][3]. Group 1: Allegations - The complaint alleges that Nutex Health Inc. and its defendants made materially false and misleading statements and failed to disclose critical information during the class period from August 8, 2024, to August 14, 2025 [3]. - Specific allegations include that HaloMD, a third-party vendor, engaged in a scheme to defraud insurance companies, leading to unsustainable revenue for Nutex [3]. - The company is accused of overstating its remediation of material weaknesses in internal controls over financial reporting, which affected its ability to account for stock-based compensation obligations [3]. - As a result of these issues, Nutex improperly classified stock-based compensation obligations as equity instead of liabilities, increasing the risk of delays in filing financial reports with the SEC [3]. Group 2: Class Action Details - Shareholders who purchased shares of Nutex during the class period are encouraged to register for the class action, with a deadline set for October 21, 2025 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit and fraud [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that inflate stock prices [5].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for failing to disclose fraudulent activities related to its third-party arbitration vendor, HaloMD, which allegedly inflated revenues through deceptive practices [2][3]. Group 1: Allegations and Financial Impact - The lawsuit claims that Nutex Health Inc. did not disclose that HaloMD was involved in a scheme to defraud insurance companies, leading to unsustainable revenue figures [2]. - It is alleged that Nutex overstated its ability to address material weaknesses in its internal controls over financial reporting, affecting its accounting for stock-based compensation [2]. - Concerns were raised about Nutex's financial performance following a report from Blue Orca Capital, which suggested that the company's recent share price surge was artificially inflated due to HaloMD's practices [3]. Group 2: Stock Performance and Market Reaction - Following the announcement of a delay in filing quarterly financial statements due to incomplete accounting adjustments, Nutex's stock price dropped over 16% [4]. - The report from Blue Orca Capital indicated that if the revenue benefits from HaloMD's practices were to cease, Nutex's financial performance could significantly decline, potentially reverting its stock to lower levels [3].

Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Nutex Health Inc. made false statements and concealed information regarding its third-party vendor HaloMD, which allegedly engaged in fraudulent activities to defraud insurance companies [2]. - It is alleged that revenues from Nutex's engagement with HaloMD were unsustainable due to the fraudulent nature of the conduct [2]. - The company reportedly overstated its remediation efforts regarding material weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [2]. - As a result of these issues, Nutex Health Inc. faced increased risks of failing to file financial reports with the SEC in a timely manner, which overstated its business and financial prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years, indicating its expertise in handling complex securities cases [4].

Accessibility StatementSkip Navigation NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nutex Health Inc. ("Nutex" or the "Company") (NASDAQ: NUTX) and certain officers. The class action, filed in the United States District Court for the Southern District of Texas, and docketed under 25- cv- 03999, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nutex securities betwee ...

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Nutex Health Inc. (NASDAQ: NUTX)?Did you purchase your shares between August 8, 2024 and August 14, 2025, inclusive?Did you lose money ...

NEW YORK , Sept. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nutex Health Inc. (NASDAQ: NUTX). ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Nutex securities between August 8, 2024, and August 14, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by October 21, 2025 [3][6]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Nutex - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices and internal controls, particularly concerning its relationship with HaloMD, a third-party vendor [5]. - Specific claims include that Nutex engaged in a scheme to defraud insurance companies, leading to unsustainable revenue and improper accounting of stock-based compensation obligations [5]. - The lawsuit asserts that these misrepresentations resulted in overstated business and financial prospects for Nutex, causing investor damages when the truth was revealed [5].